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ABSTRAK 
Leukemia Myeloid Akut (AML) adalah gangguan sel tunjang hematopoietik 
yang berlaku disebabkan ketidakupayaan sel-sel untuk berbeza dan berkembang 
secara normal. Fasa-S kinase bersekutu protein 2 (SKP2) ialah protein yang amat 
bertanggungjawab dalam pengiktirafan dan penentuan degradasi protein sasaran 
dan dikenali sebagai onkogen. Hal ini menyebabkan protein ini seringkali menjadi 
sasaran terapeutik dalam pelbagai kanser. Protein FOXO3a telah dikenal pasti  
dalam AML dan bertindak sebagai gen penindas tumor. c-MYC memainkan peranan 
penting sebagai proto-onkogen dan dikenal pasti untuk mendorong AML. Pelbagai 
eksperimen telah menunjukkan hubungan antara SKP2 dan FOXO3a serta SKP2 
dan c-MYC. Walau bagaimanapun, masih tiada maklumat yang boleh didapati 
mengenai hubungan antara SKP2, FOXO3a dan gen c-MYC dalam  translokasi t (8; 
21) AML. Dalam kajian ini, hubungan antara tahap ungkapan SKP2, FOXO3a dan 
gen c-MYC telah dikenal pasti. Sel kasumi-1 telah digunakan sebagai model AML. 
Perencatan gen SKP2 melalui gen pengantara siRNA telah dijalankan untuk 
mengenalpasti kesannya ke atas gen FOXO3a dan c-MYC pada tiga titik masa yang 
berbeza iaitu 24, 48 dan 72 jam selepas perencatan gen SKP2. siRNA telah 
diperkenalkan ke dalam Kasumi-1 melalui electroporasi dan tahap ungkapan setiap 
gen telah dikenal pasti menggunakan real-time PCR. Hasilnya menunjukkan 
penjatuhan tahap SKP2 pada semua titik masa dengan lebih daripada 50% (p 
<0.05). Walau bagaimanapun tidak ada perbezaan yang signifikan antara kedua-
dua tahap ungkapan FOXO3a dan c-MYC dengan atau tanpa perencatan gen SKP2. 
Namun, ungkapan FOXO3a gen telah dikenal pasti meningkat secara sedikit dari 24 
jam kepada 72 jam selepas perencatan gen  SKP2. Dalam usaha untuk 
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mendapatkan nilai yang signifikan, pemanjangan perencatan gen SKP2 adalah 
penting. 
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ABSTRACT 
 
Acute Myeloid Leukemia (AML) is a hematopoitic stem cell disorder causes 
by inability of the cells to differentiate and proliferate in normal manner. S-phase 
kinase–associated protein 2 (SKP2) protein is highly responsible in recognizing and 
determining the degradation of target protein and is well known for its oncogene 
property as well as for its therapeutic target in various cancers. FOXO3a protein was 
identified to present in AML and acts as tumor suppressor gene. c-MYC plays a key 
role as proto-oncogene and is recognized to induce AML. Numerous experiments 
showed correlation between SKP2 and FOXO3a as well SKP2 and c-MYC. 
However, there is no information available yet on relationship between SKP2, 
FOXO3a and c-MYC gene in AML with t(8;21) translocation. In this study, the 
correlation between expression level of SKP2, FOXO3a and c-MYC gene were 
identified. Kasumi-1 cell line was used as a model of AML with t(8;21). SKP2 
downregulation via siRNA mediated gene knockdown was carried out to identify its 
effect on FOXO3a and c-MYC gene at three different time points which were 24, 48 
and 72 hours. siRNAs were introduced into Kasumi-1 cell line via electroporation and 
the expression level of each gene were identified using real-time PCR. The result 
showed a successful knockdown of SKP2 at all different time points with more than 
50% (p<0.05). However there was no significance difference between both FOXO3a 
and c-MYC expression levels with or without SKP2 knockdown. Yet, the expression 
of FOXO3a gene was identified to increase slightly from 24 hours to 72 hours after 
SKP2 knockdown.  In order to obtain significant value, prolonged gene knockdown 
is essential. 
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CHAPTER 1: Introduction 
1.1 Research Background 
Acute Myeloid Leukemia (AML) is a hematopoietic stem cell disorder caused 
by inability of the cells to differentiate and proliferate in a normal manner, thus 
contributing to accumulation of myeloblasts,(Stone et al., 2004, Estey and Döhner, 
2006). In AML, t (8;21)(q22;q22) is the most frequently observed translocation which 
leads to the fusion of RUNX1 (AML1) with RUNX1T1 (ETO). 
Based on an experiment conducted in AML cells, there are various genes and 
proteins that affect AML such as S-phase-kinase-associated protein 2 (SKP2), MYC, 
CDKN1B (p27Kip1) and Forkhead Box O (FOXO3) proteins (Min et al., 2004, 
Chapuis et al., 2010, Brondfield et al., 2015, Ewerth et al., 2016).  
SKP2 plays its main function in recognizing and determining the degradation 
of a particular target protein. This includes cell cycle regulatory proteins such as 
cyclin-dependent kinase inhibitor 1 ( p21) , cyclin-dependent kinase inhibitor 1C ( 
p57), E2F-1 and c-MYC (Wang et al., 2012b, Chan et al., 2014) . Overexpression of 
SKP2 is abundant in various cancers such as breast, ovarian and gastric cancer (Lu 
et al., 2012, Wei et al., 2013b, Xu et al., 2013). This gene identified to plays role in 
proliferation, inhibit cell apoptosis, enhance cell invasion as well promote cell 
migration (Yin et al., 2016). Therefore, SKP2 was suggested to act as proto-
oncogene and downregulation of this gene may be a therapeutic target (Wang et al., 
2012d).  Similarly, overexpression of SKP2 and its role as an independent prognostic 
factor in AML has been identified (Min et al., 2004). However, not many studies have 
been conducted in identifying the relationship between SKP2 and AML. 
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In AML, FOXO3 gene exhibits (6;11)(q21;q23) chromosomal translocation  
(Kornblau et al., 2010). Nuclear localization of FOXO3 is essential to induce 
apoptosis and suppress proliferation in AML (Chapuis et al., 2010). Various studies 
have been reported about the relationship between SKP2 and FOXO3. For an 
example, tissues collected from ovarian cancer patient shows high expression of 
SKP2 correlated with low expression of FOXO3a and vice versa (Lu et al., 2012). 
SKP2 were identified to play a key role in FOXO3 degradation (Wang et al., 2012a), 
thus ceasing the function of FOXO. However, the relationship between SKP2 and 
FOXO3 in AML has not been established to date. 
c-MYC is recognized to act as a proto-oncogene as overexpression of this 
particular gene is crucial to induce tumorigenesis in association with other tumor 
inducing event. SKP2 were reported to enhance the transcriptional activity of c-MYC 
(Yada et al., 2004).  But some studies also emphasizes that SKP2 mediated 
degradation takes places for c-MYC (Von Der Lehr et al., 2003). Research also 
demonstrated that  MYC gene bind both in-vivo and in-vitro to SKP2 F-box protein 
(Von Der Lehr et al., 2003) contributing to the statement that these genes are linked. 
Although the expression level of SKP2, MYC, and FOXO3 affect AML, the 
exact mechanism behind this event in AML with t (8;21)  translocation remains 
unclear.  
Therefore identifying the relationship between SKP2, FOXO3a and c-MYC 
gene in AML is an interesting research question. In this experiment, Kasumi-1 cells 
were cultured as a model for AML with t (8;21)  translocation and siRNA introduced 
via electroporation in order to down-regulate SKP2 gene. The effect of SKP2 
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downregulation on both FOXO3a and c-MYC were determined by identifying the 
expression level of FOXO3 and MYC gene using real-time PCR. SPSS software was 
used for statistical analysis and the significant values were obtained by two tailed 
paired T test. The main and specific objectives of this study include: 
 
1.2 Main objective 
To study the relationship between SKP2, FOXO3, and c-MYC in leukemia. 
 
1.3 Specific objective 
1. To downregulate SKP2 gene expression levels in Kasumi-1 cells via siRNA-
mediated gene knockdown 
2. To analyze the expression level of FOXO3 and c-MYC genes after 
suppression of SKP2 
 
1.4 Hypothesis 
1. There is a correlation between SKP2, FOXO3a and c-MYC gene in Acute 
Myeloid Leukemia. 
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CHAPTER 2: Literature Review 
2.1 Acute Myeloid Leukemia 
2.1.1 Types of Acute Myeloid Leukemia  
Acute Myeloid Leukemia (AML) is a hematopoietic stem cell disorder caused 
by the inability of cells to differentiate and proliferate in the normal manner (Döhner 
et al., 2015). Due to abnormal differentiation of myeloid cells, abundance of 
immature malignant cells accumulate in bone marrow and thus fewer differentiated 
erythrocytes, thrombocytes, monocytes, and granulocytes include basophils, 
eosinophils and neutrophils (Johansson and Harrison, 2015). In the majority of AML 
cases, clonal chromosomal abnormalities were identified via chromosome banding 
analysis. Risk  factors for AML  include age,  exposure to ionizing radiation, 
petrochemicals, benzene and pesticides (O'Donnell et al., 2012). 
In adults, out of all acute leukemia, 90% was identified as AML in the United 
States year 2015. The similar study indicates risk factor of AML were higher from 
age range 30 to 65 with an approximate increase of 10 fold (Smith and Stein, 2016). 
Malaysian National Cancer Registry Report (MNCR) 2007-2011 indicates that out of 
all cancer cases which were diagnosed in Malaysia from 2007 to 2011, the 
percentage of leukemia cases were accounted for 4.4% with 5.4% in male and 3.6% 
in female as well ranked as sixth most common cancer among Malaysia population.  
To understand in detail on the disease biology, prognosis and for therapeutic 
importance, effort on the classification of AML have been made. French American 
British (FAB) initially have a key role in the classification of AML by including 
morphological differences, cytochemical and immunophenotypic analysis as 
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classification factor. The World Health Organization (WHO) classification in AML is  
more comprehensive as compared to FAB classification as WHO includes 
morphological, immunophenotypic, cytochemical, genetics and clinical features as 
AML classification factors (Johansson and Harrison, 2015). 
Table 2.1 shows Acute Myeloid Leukemia and related neoplasms classification by 
(WHO). Adapted from (Arber et al., 2016) 
1. Acute Myeloid Leukemia with recurrent genetic abnormalities 
 AML with t(8;21)(q22;q22)   
 AML with with t(6;9)(p23;q34.1) 
 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) 
 APL with t(15;17)(q22;q21) 
 AML with t(9;11)(p21.3;q23.3); 
 AML (megakaryoblastic) with t(1;22)(p13.3;q13.3)                           
 AML with inv(3)(q21.3q;q26.2) or t(3;3)(q21.3;q26.2) 
 AML with mutated NPM1                                
 AML with biallelic mutations of CEBPA 
 
2. Acute Myeloid Leukemia with myelodysplasia-related changes 
3. Therapy-related myeloid neoplasms 
4. Acute Myeloid Leukemia, not otherwise specified 
 AML with minimal differentiation 
 AML without maturation 
 Acute myelomonocytic leukemia 
 AML with maturation 
 Acute monobasic/monocytic leukemia 
 Pure erythroid leukemia 
 Acute megakaryoblastic leukemia 
 Acute basophilic leukemia 
 Acute panmyelosis with myelofibrosis 
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2.1.2 AML with t (8;21)  translocation and Kasumi-1 cell line as a model for 
Acute Myeloid Leukemia 
In AML, t (8;21) is the most frequent translocation with 12-15% of general 
AML and up to 40% out of all AML subtype M2 based on FAB classification (Peterson 
and Zhang, 2004). This translocation leads to the fusion of RUNX1 gene also known 
as AML1 present on chromosome 21 with  RUNX1T1 also known as ETO on 
chromosome 8 (Figure 2.1). This translocation is also reported to present in lymphoid 
and biphenotypic acute leukemia (Forster et al., 2016). AML1 complex plays a role 
in regulating a large number of genes that are responsible in hematopoiesis. The 
fusion of RUNX1- RUNX1T1 also known as AML1-ETO  leads to repression of 
RUNX1 gene thus blocking the differentiation of myeloid lineage (Kurokawa and 
Hirai, 2003, Johansson and Harrison, 2015). This types of translocation in leukemic 
cells were identified with a high frequency of Auer rod and granulocytic line 
maturation (Berger et al., 1982, Miyoshi et al., 1993). Translocation of t(8;21)  alone 
is not solely responsible for inducing AML, instead, an additional mutation such as 
co-operating point mutation is required for leukemogenesis. The exact mechanism 
in the development of particular mutation is not well defined, however, AML-ETO 
were reported to play role in promoting co-operating mutation (Kurokawa and Hirai, 
2003, Forster et al., 2016).       
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Figure 2.1: Schemes shows before (a) and after (b) translocation of t (8,21) 
(q22; q22) . Arrows indicate breakpoints. Usually, AML1-ETO mRNA is assayed only 
in single out of the two possible chimeric transcript type. Adapted from (Chetverina 
and Chetverin, 2010).  
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Kasumi-1 cell line is a novel t (8;21) (q22;q22) chromosomal translocation 
leukemic cell line (Asou et al., 1991). Peripheral blood of a 7 years old Japanese 
child with AML after bone marrow transplantation was used to design Kasumi-1 cell 
line (Asou et al., 1991). The second class of mutation in Kasumi-1 was identified with 
a c-kit gene mutation in the tyrosine kinase domain.  Development of Kasumi-1 cell 
line has contributed to the various finding of t(8;21) chromosomal translocation 
including morphologic, molecular level, immunophenotypic and the effect of the 
fusion as well useful in identifying its therapeutic target (Beghini et al., 2002, Larizza 
et al., 2005). For an example, studies on Kasumi-1 cell have shown that with AML1-
ETO gene expression drastically reduced,  expression level of LAT1 and RUNX3 
genes increased accordingly (Sawney et al., 2015).
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2.2 SKP2  
2.2.1 SKP2 and its role 
SKP2 (S-phase kinase–associated protein 2) is a component and substrate-
recognition subunit of SCF E3 ubiquitin ligase complex and this SKP2 is a member 
of second class F-box protein (Zhang and Wang, 2006, Chan et al., 2010).  Other 
components of SCF complex include Skp1, Cullin1 and Rbx (Figure 2.2) which plays 
a role in proteasomal degradation. Skp2 consist of the N-terminal domain, F-box 
domain through which SKP2 interacts with SKP1, and C-terminal leucine-rich (Zhang 
and Wang, 2006, Chan et al., 2010, Wang et al., 2012c, Chan et al., 2014).  
For SKP2 mediated ubiquitination of a particular substrate, ubiquitin-
activating enzyme (E1) first attaches with ubiquitin and the ubiquitin is then 
transferred to an ubiquitin-conjugating enzyme (UBC/E2). The interaction of E2 with 
E3 leads to the transportation of ubiquitin into the substrate which is recognized by 
SKP2 and this process is repeated in order to add more ubiquitin to the substrate 
(Figure 2.2), thus leading to the formation of a polyubiquitin chain which is then 
degraded by 26S proteasome (Chan et al., 2010, Wang et al., 2012c, Chan et al., 
2014).  
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Figure 2.2: The SCFskp2 E3 ubiquitin ligase complex. In this complex, SKP2 is the 
F-box protein component and function on recognizing the substrate protein. UBC/E2 
in association with E3 transfer ubiquitin to the substrates protein which is recognized 
by SKP2. Then the substrates will be degraded by proteasome S26. Adapted from 
(Kukan, 2004, Wang et al., 2012c) 
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SKP2 with the mechanism mentioned above plays its main function in 
recognizing and determining the degradation of particular or target protein which 
includes cell cycle regulatory proteins (Chan et al., 2014). Example of proteins 
targeted by SKP2 are shown in table 2.2. This suggest that SKP2 affects cell cycle 
activity and also acts as an oncogene  (Chan et al., 2010, Chan et al., 2012).  
Table 2.2: SKP2 target protein respective to its function (Wang et al., 2012b).  
         
Besides all the proteins listed in table 2.2, SKP2 is also known for its role in 
the degradation of p27. p27 acts as a tumor suppressor and negatively regulates the 
G1 cell cycle (Wang et al., 2012d). Thus, it is evident that SKP2 plays a vital role in 
Function of proteins SKP2 target proteins 
Cell cycle regulators Cyclin-dependent kinase inhibitor 1, p21 
Cyclin-dependent kinase inhibitor 1C, p57 
E2F-1 
ETS-related transcription factor Elf-4, MEF 
Retinoblastoma-like protein 2, p130 
Tob1 
Cyclin D 
Cyclin E 1 
SMAD family member 4, Smad4 
Myc 
B-Myb 
Ras association domain-containing protein 1, 
RASSF1A 
Apoptosis regulators Myc 
Forkhead box O, FOXO 
Diverse functions for 
degradation 
Origin recognition protein, Orc1p 
Chromatin licensing and DNA replication factor 
1,Cdt1 
Recombination activating gene 2, Rag-2 
BRCA2 
Cyclin-dependent kinase 9, Cdk9 
Dual specificity phosphatase 1, MKP1 
Ubiquitin specific peptidase 18, UBP43 
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cycle progression, apoptosis and a wide range of other biological processes (Wang 
et al., 2012b). 
SKP2 cDNA was transfected in MCF-7 and MDA-MB-231, breast cancer cell 
line in order to overexpress SKP2. The result showed that the upregulation of SKP2 
levels lead to cell proliferation, inhibition of cell apoptosis, enhancement of cell 
invasion and promotion of cell migration. Overexpression of SKP2 also affects the 
activity of rottlerin, a phenolic compound which was known to induce apoptosis, 
inhibit cell proliferation and inhibit cell migration (Yin et al., 2016). Research on 
breast cancer cell line which was transfected with Hepatitis B virus X-interacting 
(MCF-7-HBXIP) suggested that SKP2 plays role in HBXIP mediated breast cancer 
proliferation (Xu et al., 2013).  In Hela cell, SKP2 was downregulated and the result 
shows an increase in cell death (Wang et al., 2012a).  
SKP2 was also identified abundantly in gastric cancer cell line such as 
MGC803, SGC7901, and NCI-N87. Downregulation of SKP2 was identified to 
suppress cell proliferation, inhibit cell migration and invasion, reduce tumorigenesis 
and tumor metastasis, and induce cell apoptosis. In vivo studies in mice showed that 
SKP2 downregulation inhibits tumor growth (Wei et al., 2013a). In prostate cancer, 
SKP2 was suggested to play a role as a proto-oncogene and a potential therapeutic 
target (Wang et al., 2012d). 
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2.2.2   SKP2: Expression and Regulation 
Various compounds are responsible for suppressing or upregulating SKP2 
expression level. One of the main protein that is responsible in SKP2 downregulation 
is FOXO3 and was explained in next section. 
In MCF-7 breast cancer cell line, Hepatitis B virus X-interacting protein 
(HBXIP) was identified to upregulate SKP2 expression levels and HBXIP binds with 
E2F transcription factor 1 (E2F1) to activate SKP2 promoter activity (Xu et al., 2013).  
MCF-7 and MDA-MB-231 cells which were treated with rottlerin showed lower 
expression level of SKP2 when quantified with real time PCR (Yin et al., 2016). 
Besides, downregulation of signal transducer and activator of transcription 3 
(STAT3) in human gastric cancer cell line, SGC-7901 showed suppression of SKP2 
(Wei et al., 2013b).  
Bortezomib which plays an essential role as proteasome inhibitor identified 
induces SKP2 suppression (Li et al., 2012, Tian et al., 2013). In chronic myeloid 
leukemia cell line, AR230 and K562, bortezomib induces apoptosis by 
downregulating SKP2 expression level and causes accumulation of p27Kip1 
(Iskandarani et al., 2016). A similar result was also identified in colorectal cancer cell 
line and epithelial ovarian cancer (Uddin et al., 2008, Uddin et al., 2009).   
Compound 25 also known as SZL-P1-41 was identified via structure-based 
high-throughput virtual screening technologies for its property as SKP2 inhibitor 
(Chan et al., 2013, Yin and Wang, 2015). Compound 25 inhibit SKP2-SKP1 
interaction, thus suppressing SKP2 SCF E3 ligase activity via binding of a particular 
  14 
 
compound with SKP2. Compound 25 basically was identified not to downregulate 
SKP2 mRNA levels, instead, suppression of SKP2 at protein levels. By inhibiting 
SKP2 protein level, compound 25 stabilized expression levels of p21 and p27, 
induced cell-cycle arrest in G2/M phase and enhanced p53 mediated senescent 
response (Chan et al., 2013, Yin and Wang, 2015). 
In pancreatic cancer cells, Arsenic trioxide was reported to suppress SKP2 
mRNA levels besides stabilizing FOXO1 and p53. Similarly, Arsenic trioxide was 
also identified to downregulate SKP2 in mesothelioma cancer as well with c-myc. 
Androgen suppresses the activity of Cdk2 in phosphorylating SKP2 (Kokontis et al., 
2014). Another experiment showed that in prostate cancer cell, SKP2 suppression 
by androgen-mediated p107 dependent and independent pathways(Jiang et al., 
2012, Wang et al., 2012d). 
Besides, there are many compounds that directly interacts or indirectly plays 
role in affecting SKP2 expression level. Due to the role of SKP2 as a proto-
oncogene, many cancer research are being conducted to identify compounds that 
can responsible in downregulating SKP2 and may serve as potential therapeutic 
target in attenuating cancer.  
 
2.2.3 SKP2 and Acute Myeloid Leukemia 
Higher expression of SKP2 and its role as an independent prognostic factor 
for AML was first demonstrated from a sample of AML patients (Min et al., 2004). 
First, AML samples were collected, the expression of SKP2 was identified using 
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western blot analysis and grouped into higher SKP2 expression and lower SKP2 
expression group. Compare to lower SKP2 expression group, groups with higher 
expression of SKP2 was identified to have lower overall survival rate. Besides, SKP2 
expression was reported to positively correlate with cytoplasmic localization of the 
p27Kip1 protein. However, this study does not demonstrate the exact mechanism 
for the higher SKP2 expression in AML (Min et al., 2004, Ewerth et al., 2016).  Till 
date, very few resource are available on studies conducted in AML and SKP2 
expression level.  
Experiment conducted in Kasumi-1 cell line and SKNO1 showed prolonged 
downregulation of AML1/ETO inhibit Telomerase reverse transcriptase (TERT) 
expression (Ptasinska et al., 2012). Based on (Moses, 2015), downregulation of 
AML1/ETO and TERT in protein and RNA level is mentioned to be associated with 
reduced in SKP2 protein expression level. It is also stated that SKP2/ RB-E2F/p27 
axis plays key role in regulation of TERT by AML/ETO. 
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2.3 FOXO3a 
2.3.1 Role of FOXO as a tumor suppressor gene 
Forkhead Box O (FOXO) is one of a family member in winged-helix/forkhead 
transcriptional factor. This forkhead family is characterized by highly conserved 100 
amino acid DNA binding domain (Clark et al., 1993, Kaufmann and Knöchel, 1996, 
Kaestner et al., 2000, Fu and Tindall, 2008). FOX genes are grouped into 19 
subclasses which are FOXA to FOXS based on the homology within the region. 
(Kaestner et al., 2000, Fu and Tindall, 2008) . Family members of subclass FOXO 
in mammals are further classified into four members: FOXO1, FOXO3, FOXO4 and 
FOXO6 and play a key role as tumor suppressor gene (Calnan and Brunet, 2008, 
Xie et al., 2012).  
FOXO1 known originally as FKHR, one of the members of FOXO family were 
found to be abundantly present in B-cell lineage compare to other members of the 
same family. However, the expression level of FOXO1 was comparably less in 
classical Hodgkin Lymphoma (cHL). Nuclear translocation of FOXO1 was identified 
to induce apoptosis in five different cells of cHL includes L428, KM-H2, L1236, U-
HO1, SUP-HD. FOXO1 was also identified to induce cell cycle arrest and function in 
pro-apoptotic effect by activating tumor suppressor FOXO1 target gene such as 
NOXA,p27kip1, BCL2L11 and TNFSF10 (Xie et al., 2012). Overall survival of cancer 
cells with the effect of FOXO1 was studied in H1299 cells and the finding clearly 
indicates that nuclear translocation of FOXO1 induce cell death via apoptosis while 
cytosolic FOXO1 carry out autophagy in order to induce cell death. Ex vivo studies 
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in nude mice indicate that tumor weight was reduced in FOXO1 expressing cells but 
in absence of Atg7 or Atg5 the weight of tumor was not affected (Zhao et al., 2010). 
Experiment suggest that FOXO1a along with FOXO3a (FKHRL1) repress the 
activity of estrogen receptors- α (ER-α) and estrogen receptors- β (ER-β) proteins in 
293T, human embryonic kidney cells. Studies in MCF-7, human breast carcinoma 
cell line, suggest that FOXO3a interact with ER-α and ER-β to downregulate 
estrogen receptor (ER) transcriptional activity. In vivo studies from a mouse model 
of estrogen-dependent breast cancer further, indicates that E2-dependent tumor 
growth is suppressed by overexpression of FOXO3a.  FOXO3a was also identified 
to induce the expression of three CDK inhibitors (p27Kip1, p21Cip1, and p57Kip2) 
and overexpression of FOXO3a suppress proliferation of MCF-7 cells (Zou et al., 
2008). In Natural killer (NK)-cell neoplasms, FOXO3a and PRDM1 was suggested 
to have a role in suppression of cell proliferation compared to other genes located in 
6q21-23 (Karube et al., 2011). Besides, FOXO3a was also shown to have 
significance in AML. 
Overexpression of FOXO4(AFX) in 786-0, renal cancer cell line shows to 
induce apoptosis by increasing the expression of Bim (Wang et al., 2016). 
Expression level of FOXO4 in gastric cancer patients and gastric cancer cell line 
includes SGC7901, BGC-823, MKN28, MKN45, 9811 and AGS was identified in 
relatively lower level compared to its respective control. FOXO4 was detected to 
inhibit gastric cancer proliferation and have been shown to affect cell cycle activity 
by G1 arrest. FOXO4 was also identified to suppress gastric cancer migration, 
invasion,  tumorigenesis and metastasis (Su et al., 2014). 
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However, FOXO6 was spotted to upregulate c-MYC and induce 
tumorigenesis by regulating gastric cancer cell, SNU-16 cell proliferation (Qinyu et 
al., 2013). This suggestion opposes the role of FOXO acting as tumor suppressor 
gene. Yet, several research shows FOXO6 for its tumor suppression property. For 
an example, FOXO6 inhibit lung cancer, A549 cell proliferation. During post-
transcription or translation level, FOXO6 plays a key role in inducing p53 protein 
expression (Hu et al., 2015). 
Overall, FOXO is known for tumor suppression property due to its role in cell 
cycle arrest, pro-apoptotic effect by activating tumor suppressor gene, suppressing 
cancer cells migration as well invasion, tumorigenesis, metastasis and inhibiting 
cancer cell proliferation. 
 
2.3.2 FOXO3a: One of FOXO family present in Acute Myeloid Leukemia 
In Acute Myeloid Leukemia, the FOXO3 gene was identified at 
(6;11)(q21;q23) chromosomal translocation  (Kornblau et al., 2010). PCR screening 
of human leukemic cell line K562 cDNA library shows that in this chromosomal 
translocation site, FOX03 gene is located to fuse with MLL gene (Figure 2.3) (Hillion 
et al., 1997, Katoh and Katoh, 2004).  
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Figure 2.3: Nucleotide and predicted the amino acid sequence of fused MLL-
FOXO3a cDNA. Adapted from (Hillion et al., 1997). 
 
In order to identify the FOXO1, FOXO3a and FOXO4 expression pattern in 
AML, primary AML cells of patients and human Acute Monocytic Leukemia cell line, 
MV4-11 were analyzed. The result clearly shows an abundance of FOXO3a mRNA 
level. When western blot was carried out, there was the detection of FOXO1 level in 
only some patients and absent of FOXO4. However, all  three proteins were 
expressed abundantly in human leukemia cell lines, MOLM-14 (Chapuis et al., 
2010). This experiment also emphasizes that in AML blast cells, FOXO3 was 
constantly expressed compare to other FOXO family member. 
Nuclear localization of FOXO3a is essential to induce apoptosis and suppress 
proliferation in AML (Chapuis et al., 2010). However, FOXO3a phosphorylation 
induces FOXO3a translocation from nucleus to the cytoplasm, thus suppressing 
FOXO3a activity (Brunet et al., 1999, Yang and Hung, 2009, Chapuis et al., 2010, 
Thépot et al., 2011). 
Experiment from AML blast cells and MV4-11/FOXO3a-GFP cells shows 
presence of inactive FOXO3 due to its translocation from nucleus to cytoplasm and 
both AKT and ERK are not responsible for this translocation. When Nemo-
antagonistic peptide 29, an inhibitor of IKK signaling pathway is introduced in both 
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AML cells and MV4-11/FOXO3a-GFP cells, nuclear translocation of FOXO3a was 
strongly induced. This statement clarifies that IKK plays a key role in FOXO3a 
cytoplasmic translocation and experiment shows that phosphorylation on S644 is 
essential for this particular function of IKK (Chapuis et al., 2010). 
Hypomethylation agents such as azacitidine are identified to induce nuclear 
translocation of FOXO3a. Both azacitidine and decitabine were identified to induce 
FOXO3a dephosphorylation. When SKM-1 cell line which was established from 
Myelomonocytic Leukemia in Myelodysplastic Syndrome, were treated with 
azacitidine, the level of FOXO3a mRNA increases. The experiment was then 
proceeded using patient-derived AML cells to determine the FOXO3a translocation 
and apoptosis properties after treatment with hypomethylation agent. The result 
clearly shows a correlation between azacitidine-treated cells’ nuclear FOXO3a 
translocation and apoptosis. However, when the cells were treated with decitabine, 
there was no significant correlation between nuclear FOXO3a translocation and 
apoptosis. This experiment clearly indicates the application of hypomethylation 
agents to induce FOXO3a dephosphorylation or nuclear translocation in AML 
(Thépot et al., 2011). 
Although it was stated FOXO3a nuclear translocation is essential to induce 
apoptosis in AML cells (Chapuis et al., 2010), some experiment indicates an 
opposing result. In both MOLM-14 and MM6 cells, knockdown of FOXO3 is shown 
to increase its phagocytic property. Besides, the rate of apoptosis in CD11+ cells 
expressing FOXO3 shRNA increased. Yet, the experiment also indicates that 
ablation of FOXO1, FOXO3, and FOXO4 in MLL-AF9 leukemic bone marrow cells 
from mice shows an increase in expression of CD11b and Gr-1 (both are mature 
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myeloid cellular markers) and morphological changes indicates myeloid maturation 
(Sykes et al., 2011). 
The experiment was conducted in order to identify the expression pattern of 
FOXO3a and its adverse effect in cytogenetically normal AML patients. The result 
shows that patient with a higher level of FOXO3a gene expression have a shorter 
overall survival ( the period from diagnosis to death/last follow-up) and relapse-free 
survival (period of complete remission to hematological relapse/last follow-up) than 
patient showing lower FOXO3 gene expression (Santamaría et al., 2009). Similarly, 
FOXO1, FOXO3 AND FOXO4 ablation in mice with MLL-AF9 positive AML shows a 
longer latency (Sykes et al., 2011).  
 
2.3.3 Gene regulation of FOXO: Phosphorylation and Ubiquitination      
The major mechanisms that affect FOXO transcriptional factor are 
phosphorylation and ubiquitination. Research have shown that various factors are 
responsible for these two mechanisms. The factors involved include AKT, 14-3-3, 
SKP2 and MDM2. Phosphorylation of FOXO at different sites leads to localization of 
FOXO from nucleus to the cytoplasm. This localization pattern affects FOXO 
transcriptional activity as FOXO is shown to be inactive during its cytoplasmic 
localization state. It is also suggested that the rate of phosphate group being 
removed from the phosphorylation site in FOXO by phosphatase may influence the 
localization pattern (Calnan and Brunet, 2008). 
Although (Chapuis et al., 2010) shows that IκB kinase( IKK) was identified to 
overcome the Protein kinase B (AKT) activity in cytoplasmic localization of FOXO, 
